4//SEC Filing
Goncalves Joana 4
Accession 0000907654-25-000023
CIK 0000907654other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 5:38 PM ET
Size
17.9 KB
Accession
0000907654-25-000023
Insider Transaction Report
Form 4
Goncalves Joana
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-19$6.84/sh+3,500$23,940→ 5,018 total - Exercise/Conversion
Common Stock
2025-12-19$7.80/sh+3,500$27,300→ 8,518 total - Sale
Common Stock
2025-12-19$28.53/sh−641$18,289→ 7,877 total - Sale
Common Stock
2025-12-19$29.62/sh−1,787$52,935→ 6,090 total - Sale
Common Stock
2025-12-19$30.70/sh−1,492$45,806→ 4,598 total - Sale
Common Stock
2025-12-19$31.58/sh−3,080$97,263→ 1,518 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-19−3,500→ 225,063 totalExercise: $6.84Exp: 2034-05-06→ Common Stock (3,500 underlying) - Exercise/Conversion
Employee Warrant (right to buy)
2025-12-19−3,500→ 196,492 totalExercise: $7.80Exp: 2034-07-14→ Common Stock (3,500 underlying)
Footnotes (8)
- [F1]Includes 191 shares acquired under the Oruka stock purchase plan on December 8, 2024, 661 shares acquired under the Oruka stock purchase plan on June 8, 2025 and 666 shares acquired under the Oruka stock purchase plan on December 8, 2025.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $29.12, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $30.13, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.18, inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.00, inclusive.
- [F7]The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
- [F8]The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Issuer
Oruka Therapeutics, Inc.
CIK 0000907654
Entity typeother
Related Parties
1- filerCIK 0001756991
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 5:38 PM ET
- Size
- 17.9 KB